Company intelligence / Profile preview

Levo Therapeutics

Skokie, Illinois, United Statespmc.ncbi.nlm.nih.gov ↗

Ownership: Private
Employees: ~20
Development stage: Phase 3

Overview

Phase 3 CARE-PWS study of LV-101 (intranasal carbetocin) showed statistically significant improvement on the Hyperphagia Questionnaire for Clinical Trials at the 3.2 mg dose, but did not demonstrate statistically significant effect on the Children's Yale-Brown Obsessive Compulsive Scale. FDA recommended an additional clinical study to confirm results of the 3.2 mg dose.[2][5]

Therapeutic areas: Rare Diseases
Modalities: Peptides
Industry: Biotech

Drug pipeline

1 asset

carbetocin

Phase 3

Indications: Prader-Willi syndrome

Beyond the preview

Go deeper on Levo Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Levo Therapeutics.

Explore the full profile